Merck & Co., Inc. (NYSE:MRK) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Merck & Co., Inc. (NYSE:MRK) have been assigned an average rating of “Moderate Buy” from the twenty-five brokerages that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $151.3182.

A number of research firms have weighed in on MRK. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Jefferies Financial Group cut shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Leerink Partners lifted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Royal Bank Of Canada lowered shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and boosted their target price for the company from $142.00 to $150.00 in a report on Thursday, August 20th.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts raised price targets: HSBC lifted its target from $150 to $172 and maintained a “buy” rating, while Guggenheim raised its target to $170. Leerink Partners also increased its target from $127 to $161 and assigned an “outperform” rating. These revisions indicate continued confidence in Merck’s earnings potential and pipeline. Guggenheim Increases Merck Price Target
• Positive Sentiment: Pipeline strategy may help address Keytruda risks: Merck is pairing antibody-drug conjugates with Keytruda in women’s cancer treatments, an effort to expand its oncology franchise and offset the eventual impact of Keytruda’s patent cliff. Merck Pairs ADCs With Keytruda
• Neutral Sentiment: Investors are reassessing Merck’s valuation: A comparison with Eli Lilly highlights that Merck is trading at a higher valuation despite its slower expected growth, prompting questions about whether its pipeline, cash generation and defensive characteristics justify the premium. Merck Stock Versus Eli Lilly
• Neutral Sentiment: Market attention remains elevated: Merck was among the stocks most watched by Zacks users, suggesting strong investor interest but not necessarily a change in fundamentals. Merck Investor Attention
• Negative Sentiment: Shares declined with the broader market and underperformed during the session: The trading update provided no new company-specific catalyst, leaving valuation concerns and the Keytruda patent-cliff debate as the primary pressures on the stock.

Insider Buying and Selling

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Deluca sold 20,784 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last three months. Insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Pinnbrook Capital Management LP raised its holdings in Merck & Co., Inc. by 95.2% in the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after purchasing an additional 11,355 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $11,470,000. Cibc World Market Inc. increased its position in shares of Merck & Co., Inc. by 32.6% during the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock valued at $137,022,000 after buying an additional 320,143 shares during the period. Russell Investments Group Ltd. increased its position in shares of Merck & Co., Inc. by 2.0% during the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock valued at $331,931,000 after buying an additional 51,393 shares during the period. Finally, Handelsbanken Fonder AB raised its stake in Merck & Co., Inc. by 13.9% in the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after buying an additional 224,752 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Down 1.9%

Shares of MRK opened at $144.68 on Friday. The stock’s 50-day moving average price is $136.22 and its two-hundred day moving average price is $124.26. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92. The company has a market capitalization of $356.96 billion, a PE ratio of 115.75, a PEG ratio of 6.42 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.